| GTO ID | GTC2903 |
| Trial ID | NCT05202782 |
| Disease | Diffuse Large B-Cell Lymphoma | High-Grade B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Primary Mediastinal B-Cell Lymphoma | B-Cell Lymphoma | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Intravascular Large B-Cell Lymphoma |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Co-treatment | Zanubrutinib |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | Northwestern University |
| Other ID(s) | NU 20H09|NCI-2021-08866|STU00215064|NU 20H09|P30CA060553 |
| Cohort 1 | |||||||
|
|||||||